Dianthus Therapeutics Inc (NAS:DNTH)
$ 22.55 0.81 (3.73%) Market Cap: 661.83 Mil Enterprise Value: 261.52 Mil PE Ratio: 0 PB Ratio: 1.71 GF Score: 20/100

Magenta Therapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript

Jun 11, 2020 / 12:50PM GMT
Kyuwon Choi;Jason
Goldman Sachs Group, Inc., Research Division - Equity Analyst

Okay. We'll continue with the next session. Good morning, everyone. I'm Paul Choi, the SMid cap Biotechnology Analyst at Goldman Sachs. And with our next session, I'm very pleased to host Magenta Therapeutics. Joining us from Magenta, we have a very -- a nice large group here, including Jason Gardner, CEO; Jason Ryan, CFO. We're also pleased to have John Davis, the CMO; and Manisha Pai from IR. As with the prior sessions during the conference, I'll provide some introductory remarks and then turn it over to Jason Gardner for some opening comments. After that, we'll go into the Q&A. And then along the way, if any investors or clients have questions, please feel free to submit them along the way via the Goldman Sachs' research portal. Alternatively, you can e-mail them to me directly and time permitting at the end, I'll try and squeeze in a question or 2, should any be submitted. Otherwise, with that, I'll turn it over to Jason Gardner for some opening comments, and then we'll go into the Q&A. Jason?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot